The management of patients with mild hepatitis C

Acta Gastro-Enterologica Belgica

Volumn 68, Issue 3, 2005, Pages 314-318

  Verslype, C ^a   Michielsen, P ^b   Adler, M ^c   Orlent, H ^d   Sprengers, D ^d   Delwaide, J ^e   D'Heygere, F ^f   Langlet, Ph ^g   Brenard, R ^h   Colle, I ⁱ   Reynaert, H ^j   Starkel P ^k   Henrion, J ^l  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d AZ Sint Janshospitaal ^*  (Belgium)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f CAZK Groeninghe Hospital   (Belgium)

^g BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^h Hopital St Joseph   (Belgium)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^l Hospital de Jolimont   (Belgium)

more..

Author keywords

Liver biopsy; Mild hepatitis C; Persistently normal ALT

Indexed keywords

AMINOTRANSFERASE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY;

ANTIVIRAL AGENTS; BIOPSY; HEPATITIS C, CHRONIC; HUMANS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 26944490728     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C, 10-12 June 2002. Hepatology, 2002, 36: S3-20.
2. ALBERTI A., BENVEGNÙ L., BOCCATO S., FERRARI A., SEBASTIANI G. Natural history of initially mild chronic hepatitis C. Dig. Liver Dis., 2004, 36: 646-54.
3. WEISSENBORN K., KRAUSE J., BOKEMEYER M., HECKER H., SCHULER A., ENNEN J.C., AHL B., MANNS M.P., BOKER K.W. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J. Hepatol., 2004, 41: 845-51.
4. ALBERTI A., NOVENTA E, BENVEGNÙ L., BOCCATO S., GATTA A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann. Intern. Med., 2002, 137: 961-964.
5. KIM H.C., NAM C.M., JEE S.H., HAN K.H., OH D.K., SUH I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br. Med. J., 2004, 328: 983.
6. PRATI D., TAIOLI E., ZANELLA A., DELLA TORRE E., BUTELLI S., DE VECCHIO E., VIANELLO L., ZANUSO F., MOZZI F, MILANI S., CONTE D., COLOMBO M., SIRCHIA G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med., 2002, 137: 1-10.
7. ALBERTI A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J. Hepatol., 2005, 42: 266-74.
8. ZEUZEM S., DIAGO M., GANE E., REDDY K.R., POCKROS P., PRATI D., SHIFFMAN M., FARCI P., GITLIN N., O'BRIEN C.B., LAMOUR F, LARDELLI P., PEGASYS Study NR16071 Investigator Group. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology, 2004, 127: 1724-32.
9. ROSSI E., ADAMS L., PRINS A., BULSARA M., DE BOER B., GARAS G., MACQUILLAN G., SPEERS D., JEFFREY G. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin. Chem., 2003, 49: 450-4.
10. CALLEWAERT N., VAN VLIERBERGHE H., VAN HECKE A., LAROY W., DELANGHE J., CONTRERAS R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med., 2004, 10: 429-34.
11. STRADER D.B., WRIGHT T., THOMAS D.L., SEEFF L.B. Diagnosis, management and treatment of hepatitis C. Hepatology, 2004, 39: 1147-1171.
12. MARCELLIN P., ASSELAH T., BOYER N. Fibrosis and disease progression in hepatitis C. Hepatology, 2002, 36: S47-S56.
13. GHANY M.G., KLEINER D.E., ALTER H., DOO E., KHOKAR F., PROMRAT K., HERION D., PARK Y., LIANG T.J., HOOFNAGLE J.H. Progression of fibrosis in chronic hepatitis C. Gastroenterology, 2003, 124: 97-104.
14. HUI C.K., BELAYE T., MONTEGRANDE K., WRIGHT T.L. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J. Hepatol., 2003, 38: 511-517.
15. SALOMON J.A., WEINSTEIN M.C., HAMMITT J.K., GOLDIE S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. J. Am. Med. Assoc., 2003, 290: 228-237.
16. MANNS M.P., MCHUTCHISON J.G., GORDON S.C., RUSTGI V.K., SHIFFMAN M., REINDOLLAR R. GOODMAN Z.D., KOURY K., LING M., ALBRECHT J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet, 2001, 358: 958-965.
17. FRIED M.W., SHIFFMAN M.L., REDDY K.R., SMITH C., MARINOS G., GONCALES FR. JR. HAUSSINGER D., DIAGO M., CAROSI G., DHUMEAUX D., CRAXI A., LIN A., HOFFMAN J., YU J. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N. Engl. J. Med., 2002, 347: 975-982.
18. ANNEMANS L., WARIE H., NECHELPUT M., PERAUX B. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN α-2a in hepatitis C virus infected patients. Acta Gastroenterol. Belg., 2004, 67: 1-8.
19. MICHIELSEN P., BRENARD R., BOURGEOIS N., DE GALOCSY CH., DELWAIDE J., HENRION J., HORSMANS Y., NEVENS F., REYNAERT H., ROBAEYS G., SPRENGERS D., VAN VLIERBERGHE H., Steering Committee Belgian Association for the Study of the Liver. Hepatitis C: screening, treatment and prevention practical guidelines. Acta Gastroenterol. Belg., 2003, 66: 15-9.
20. GRIEVE R., ROBERTS J., WRIGHT M., SWEETING M., DEANGELIS D., ROSENBERG W., BASSENDINE M., MAIN J., THOMAS H. Cost-effectiveness of interferon α or peginterferon β, with ribavirin for histologically mild chronic hepatitis C. Gut, 2005 (Epub June 30, 2005).